Assessment of PD-L1 expression level using immunohistochemistry

SK Seo Ree Kim
SC Sang Hoon Chun
JK Joo Ri Kim
SK Sang-Yeob Kim
JS Jun Young Seo
CJ Chan Kwon Jung
BG Bo-Mi Gil
JK Jeong-Oh Kim
YK Yoon Ho Ko
IW In Sook Woo
BS Byoung Yong Shim
SH Sook-Hee Hong
JK Jin Hyoung Kang
request Request a Protocol
ask Ask a question
Favorite

We used archival tumor tissues obtained by core needle biopsy or excisional biopsy at the initial diagnosis. PD-L1 expression is widely used as a key predictive biomarker for PD-1/PD-L1 blockade and has been approved as a companion diagnostic test for pembrolizumab (Kytruda®; Merck, Kenilworth, NJ, USA). PD-L1 expression was assessed using immunohistochemistry (IHC) in formalin-fixed paraffin-embedded tumor tissue using the PD-L1 IHC 22C3 pharmDx assay (Dako, Santa Clara, CA, USA) at a hospital pathology laboratory. These data were determined by means of a Combined Positive Score, which includes the number of PD-L1 positive cells (tumor cells, lymphocytes, macrophages) divided by the total number of viable tumor cells, multiplied by 100.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A